ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. m.
01 est. vs.
42 billion est. vs.
2% below its 52-week highAnalyst view: Buy consensus, $176 target (11 analysts)ExxonMobil has beaten estimates in seven of its past eight quarters, with production growth and oil-market exposure central to the test after a powerful run in the stock. In Q2, it missed on EPS but beat revenue.
On its July call, management highlighted record Permian Basin and Guyana production while saying a fifth Guyana FPSO was on track to start by year-end. Barclays maintained its Overweight rating while raising its target to $200 from $177 on Oct.
m. 77 est.
vs. 35 billion est.
vs. 6% below its 52-week highAnalyst view: Buy consensus, $290 target (21 analysts)AbbVie has beaten estimates in five of its past eight quarters, and investors will be looking for continued strength from newer medicines and the durability of the company’s growth profile.
In Q2, it missed on EPS but beat revenue. On its July call, management pointed to double-digit sales growth and continued Dupixent momentum while raising its full-year revenue guidance.
Goldman Sachs maintained its Neutral rating while raising its target to $294 from $258 on Oct. m.
82 est. vs.
41 billion est. vs.
3% below its 52-week highAnalyst view: Buy consensus, $227 target (13 analysts)Chevron has beaten estimates in six of its past eight quarters, making production growth, refining performance and capital discipline the key read-throughs for an energy group that has rallied sharply. In Q2, it beat on both EPS and revenue.
S. upstream production and refinery throughput as evidence of operating momentum.
Morgan Stanley maintained its Overweight rating while raising its target to $226 from $218 on Oct. m.
44 est. vs.
01 billion est. vs.
1% below its 52-week highAnalyst view: Strong Buy, $198 target (1 analyst)AstraZeneca has beaten estimates in five of its past eight quarters, while the stock’s distance from its 52-week high leaves the pipeline and demand for innovative medicines under close scrutiny. In Q2, it beat on EPS but missed revenue.
m. 63 est.
vs. 87 billion est.
vs. 5% below its 52-week highAnalyst view: Buy consensus, $52 target (7 analysts)BP has beaten estimates in six of its past eight quarters, with investors weighing improving profitability and shareholder returns against production disruptions and the company’s push to simplify its portfolio.
In Q2, it beat on both EPS and revenue. On its August call, management outlined priorities including balance-sheet improvement, disciplined investment and lower costs.
TD Cowen maintained its Hold rating while raising its target to $49 from $47 on Oct. m.
63 est. vs.
23 billion est. vs.
8% below its 52-week highSanofi has beaten estimates in five of its past eight quarters, and the report will test whether new pharmaceutical launches and Dupixent can offset pressure on earnings. In Q2, it beat on both EPS and revenue.
m. 13 est.
vs. 72 billion est.
vs. 2% below its 52-week highAnalyst view: Buy consensus, $412 target (11 analysts)General Dynamics has beaten estimates in seven of its past eight quarters, putting the focus on execution across its defense programs and whether its backlog continues to translate into steady growth.
In Q2, it beat on both EPS and revenue. On its July call, management reported higher revenue and operating earnings, with a record backlog supporting the longer-term outlook.
RBC Capital maintained its Sector Perform rating while cutting its target to $360 from $410 on Oct. m.
71 est. vs.
56 billion est. vs.
2% below its 52-week highAnalyst view: Buy consensus, $823 target (18 analysts)Regeneron Pharmaceuticals has beaten estimates in seven of its past eight quarters, and the test is whether Dupixent, Eylea HD and Libtayo can maintain the company’s growth momentum. In Q2, it beat on both EPS and revenue.
On its July call, management highlighted new sales highs for all three medicines alongside double-digit revenue growth. Canaccord Genuity maintained its Buy rating while raising its target to $922 from $875 on Oct.
m. 49 est.
vs. 27 billion est.
vs. 8% below its 52-week highAnalyst view: Buy consensus, $152 target (8 analysts)Canadian National Railway has beaten estimates in four of its past eight quarters, leaving volume growth, productivity and the company’s network expansion agreements as the main operational markers.
In Q2, it beat on both EPS and revenue. On its July call, management pointed to volume growth and productivity gains while highlighting agreements with Union Pacific to expand access to Kansas City and Mexico.
Citigroup maintained its Buy rating while cutting its target to $143 from $151 on Oct. m.
92 est. vs.
33 billion est. vs.
S. execution and cash generation.
In Q2, it beat on both EPS and revenue. On its July call, management pointed to organic sales growth across most divisions and categories, alongside higher free cash flow.
JP Morgan maintained its Overweight rating while raising its target to $104 from $103 on Oct.
